title: Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population.
abstract: The emergence of a new influenza A virus (H1N1) variant in 2009 led to a worldwide vaccination program, which was prepared in a relatively short period of time. This study investigated the humoral immunity against this virus before and after vaccination with a 2009 influenza A virus (H1N1) monovalent MF59-adjuvanted vaccine, as well as the persistence of vaccine-induced antibodies. Our prospective longitudinal study included 498 health care workers (mean age, 43 years; median age, 44 years). Most (89%) had never or only occasionally received a seasonal influenza virus vaccine, and 11% were vaccinated annually (on average, for >10 years). Antibody titers were determined by a hemagglutination inhibition (HI) assay at baseline, 3 weeks after the first vaccination, and 5 weeks and 7 months after the second vaccination. Four hundred thirty-five persons received two doses of the 2009 vaccine. After the first dose, 79.5% developed a HI titer of ≥40. This percentage increased to 83.3% after the second dose. Persistent antibodies were found in 71.9% of the group that had not received annual vaccinations and in 43.8% of the group that had received annual vaccinations. The latter group tended to have lower HI titers (P=0.09). With increasing age, HI titers decreased significantly, by 2.4% per year. A single dose of the 2009 vaccine was immunogenic in almost 80% of the study population, whereas an additional dose resulted in significantly increased titers only in persons over 50. Finally, a reduced HI antibody response against the 2009 vaccine was found in adults who had previously received seasonal influenza virus vaccination. More studies on the effect of yearly seasonal influenza virus vaccination on the immune response are warranted.
authors.affiliation: Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital, P.O. 747, 5000 AS Tilburg, Netherlands. i.huijskens@gmail.com
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Huijskens
authors.forename: John
authors.initials: J
authors.lastname: Rossen
authors.forename: Paul
authors.initials: P
authors.lastname: Mulder
authors.forename: Ruud
authors.initials: R
authors.lastname: van Beek
authors.forename: Hennie
authors.initials: H
authors.lastname: van Vugt
authors.forename: Johannes
authors.initials: J
authors.lastname: Verbakel
authors.forename: Guus
authors.initials: G
authors.lastname: Rimmelzwaan
authors.forename: Marion
authors.initials: M
authors.lastname: Koopmans
authors.forename: Marcel
authors.initials: M
authors.lastname: Peeters
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D006282:Health Personnel; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007117:Immunization, Secondary; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011136:Polysorbates / Q000008:administration & dosage; D013185:Squalene / Q000008:administration & dosage / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome; D014611:Vaccination / Q000706:statistics & numerical data*; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene